Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology

被引：2

作者：

He, Liqi ^{[1
]}

Zhang, Meng Yao ^{[1
]}

Cox, Matthew ^{[1
]}

Zhang, Qian ^{[1
]}

Donnell, Andrew F. ^{[2
]}

Zhang, Yong ^{[2
]}

Tarby, Christine ^{[2
]}

Gill, Patrice ^{[2
]}

Subbaiah, Murugaiah A. M. ^{[3
]}

Ramar, Thangeswaran ^{[3
]}

Reddy, Maheswara ^{[3
]}

Puttapaka, Vijaya ^{[3
]}

Li, Yi-Xin ^{[1
]}

Sivaprakasam, Prasanna ^{[2
]}

Critton, David ^{[2
]}

Mulligan, Dawn ^{[2
]}

Xie, Chunshan ^{[2
]}

Ramakrishnan, Radha ^{[2
]}

Nagar, Jignesh ^{[3
]}

Dudhgaonkar, Shailesh ^{[3
]}

Murtaza, Anwar ^{[2
]}

Oderinde, Martins S. ^{[2
]}

Schieven, Gary L. ^{[2
]}

Mathur, Arvind ^{[2
]}

Gavai, Ashvinikumar V. ^{[2
]}

Vite, Gregory ^{[2
]}

Gangwar, Sanjeev ^{[1
]}

Poudel, Yam B. ^{[1
]}

机构：

[1] Bristol Myers Squibb, Res & Dev, Redwood City, CA 94063 USA

[2] Bristol Myers Squibb, Res & Dev, Princeton, NJ 08543 USA

[3] Biocon Bristol Myers Squibb R&D Ctr, Bangalore 560099, India

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2024年 / 15卷 / 02期

关键词：

TLR7; agonist; Tumor; Immuno-oncology; Cancer; PD1;

D O I：

10.1021/acsmedchemlett.3c00456

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Small molecule toll-like receptor (TLR) 7 agonists have gathered considerable interest as promising therapeutic agents for applications in cancer immunotherapy. Herein, we describe the development and optimization of a series of novel TLR7 agonists through systematic structure-activity relationship studies focusing on modification of the phenylpiperidine side chain. Additional refinement of ADME properties culminated in the discovery of compound 14, which displayed nanomolar reporter assay activity and favorable drug-like properties. Compound 14 demonstrated excellent in vivo pharmacokinetic/pharmacodynamic profiles and synergistic antitumor activity when administered in combination with aPD1 antibody, suggesting opportunities of employing 14 in immuno-oncology therapies with immune checkpoint blockade agents.

引用

页码：189 / 196

页数：8

共 48 条

[41] Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7/8 agonist
Nuhn, Lutz
Van Hoecke, Lien
Deswarte, Kim
Schepens, Bert
Li, Yupeng
Lambrecht, Bart N.
De Koker, Stefaan
David, Sunil A.
Saelens, Xavier
De Geest, Bruno G.
BIOMATERIALS, 2018, 178 : 643 - 651
[42] MEDI 218-Synthesis and SAR of TLR7 and TLR8 small molecule immune response modifiers: Novel alkylamino and alkoxy functionalized imidazo[4,5-c]quinolines
Krepski, Larry R.
Manske, Karl J.
Griesgraber, George W.
Duffy, Daniel E.
Moseman, Joan T.
Dressel, Luke T.
Stoermer, Doris
Heppner, Philip D.
Kshirsagar, Tushar A.
Dellaria, Joseph F.
Gibson, Sheila J.
Wurst, Lindsay R.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
[43] A novel small molecule compound possesses immunomodulatory properties on bone marrow-derived dendritic cells via TLR7 signaling pathway and alleviates the development of SLE
Gao, Sheng
Yuan, Linbo
Li, Cunyu
Han, Liping
Hua, Chunyan
INTERNATIONAL IMMUNOPHARMACOLOGY, 2017, 47 : 47 - 52
[44] MEDI 216-Design and synthesis of small molecule TLR7 and TLR8 immune response modifiers: Investigation of novel A-ring substituted imidazo[4,5-c]quinolines
Rice, Michael J.
Merrill, Bryon A.
Hays, David S.
Niwas, Shri
Danielson, Michael E.
Wurst, Joshua R.
Lundquist, Gregory D.
Haraldson, Chad A.
Gerster, John F.
Heppner, Philip D.
Kshirsagar, Tushar A.
Johannessen, Sarah C.
Kavanagh, Maureen A.
Lindstrom, Kyle J.
Prince, Ryan B.
Amos, David T.
Radmer, Matthew R.
Squire, David J.
Langer, Scott E.
Jacobsen, John R.
Bonk, Jason D.
Anderson, Jason C.
Strong, Sarah A.
Van Keuren, Steven A.
Wurst, Lindsay R.
Gibson, Sheila J.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
[45] Lyc-55716: A novel small-molecule RORγ agonist immuno-oncology agent: Rationale for tumor selection and clinical evaluation of gastric and esophageal carcinoma in phase 2a expansion.
Weems, Garry Alan
Hu, Xiao
Liu, Xikui
Li, Hongxiu
Bogdan, Madhumita
Gao, Yilin
Fox, Brian
Wilkins, H. Jeffrey
Carter, Laura
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[46] Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Tumor selection and evaluation of renal cell and bladder cancer for inclusion in phase 2a expansion.
Hu, Xiao
Liu, Xikui
Li, Hongxiu
Zawidzka, Elizabeth
Weems, Garry Alan
Gao, Yilin
Fox, Brian
Wilkins, H. Jeffrey
Carter, Laura
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[47] MEDI 219-Design and synthesis of small molecule TLR7 and TLR8 immune response modifiers (IRMs): The preparation and biological evaluation of oxazino[4',3':1,2]imidazo[4,5-c]quinolines
Griesgraber, George W.
Rice, Michael J.
Johannessen, Sarah C.
Kshirsagar, Tushar A.
Danielson, Michael E.
Maye, Peter V.
Gerster, John F.
Lindstrom, Kyle J.
Celebi, Azim C.
Reiter, Michael J.
Wurst, Lindsay R.
Gibson, Sheila J.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
[48] Novel, potent, and selective small-molecule inhibitors modulating immuno-oncology targets CD73, A2A/A2B adenosine receptors and CSF1R discovered via DNA-encoded library screening
McRiner, Andrew J.
Andersen, Jannik N.
Fouser, Lynette A.
Zhang, Junyi
Certel, Kaan
Cuozzo, John
Chan, Betty
Chandran, Ragunath
Clark, Matt
Gikunju, Diana
Hupp, Christopher D.
Keefe, Anthony D.
Liu, Julie
Liu, Yanbin
Monteiro, Michael
Olszewski, Allison
Von Rechenberg, Moritz
Resnicow, Daniel
Thomson, Heather A.
Troast, Dawn M.
Wang, Zooey
Westlund, Neil
Zhang, Ying
Zhou, Fei
Zhu, Xiaotian
Briskin, Michael
Ezzeddine, Diala
CANCER RESEARCH, 2019, 79 (13)

← 1 2 3 4 5 →